Results from the phase 3 KarMMa-3 trial of ide-cel vs standard of care in previously treated multiple myeloma led to the FDA approval.
Approval Alert | Ide-Cel in Previously Treated Multiple Myeloma
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
4
Cevostamab Combo Shows Enduring Responses in R/R Multiple Myeloma
5
